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Human epidermal growth factor receptor 2 (HER2) overexpression occurs in up to 30% of breast cancers
and is a marker of aggressive disease. While HER2-targeted therapies have improved outcomes in these
tumors, resistance to these agents develops in a large proportion of patients. Determining molecular
mechanisms underlying resistance might help improve outcomes for patients with HER2-positive dis-
ease by allowing development of strategies to overcome resistance. Activation of signaling pathways
involving the phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/
mTOR) pathway might contribute to the development of resistance to HER2-targeted therapies. Several
inhibitors of this pathway are under investigation in this disease setting and phase 3 data for everolimus
in combination with trastuzumab and chemotherapy in trastuzumab-refractory, advanced disease are
promising. In this review, molecular mechanisms underlying resistance to HER2-targeted therapies are
considered and evidence for strategies to manage resistance is evaluated, including the use of inhibitors
of the PI3K/Akt/mTOR pathway.
© 2015 The Author. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Human epidermal growth factor receptor 2 (HER2) is a member
of the ErbB family of receptor tyrosine kinases [1]. HER2 mediates
signal transduction through heterodimerization with other ErbB
family members, including Erb1, Erb3, and Erb4, causing auto-
phosphorylation of the tyrosine kinase domain of the receptor and
subsequent activation of downstream pathways, including the
phosphoinositide 3-kinase/protein kinase B/mammalian target of
rapamycin (PI3K/Akt/mTOR) and Ras/Raf/mitogen-activated pro-
tein kinase (MAPK) pathways. Up to 30% of invasive breast cancers
overexpress HER2 [2], leading to stimulation of pathways involvedase B; CI, conﬁdence interval;
es; EGFR, epidermal growth
or receptor 2; HER2þ, HER2-
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td. This is an open access article uin cell proliferation and survival [3]. HER2 overexpression is a
marker of aggressive disease [4], and is correlated with age older
than 50 years and higher T stage and histologic grade [5].
Identiﬁcation of the dysregulated HER2 pathway in breast
cancer pathogenesis has led to the development of HER2-targeted
therapies [6,7]. Trastuzumab is a monoclonal antibody that has
shown improved overall survival (OS) in the ﬁrst-line setting in
combination with chemotherapy in patients with HER2-positive
(HER2þ) advanced disease [8,9] and as adjuvant therapy when
used in combination with or sequentially after chemotherapy
[10,11], and is recommended as part of neoadjuvant regimens in
HER2þ disease [12]. Pertuzumab is a monoclonal antibody that
prevents HER2 from couplingwith other ErbB familymembers [13],
and is approved for use in combination with trastuzumab and
docetaxel in patients who have not received previous HER2-
targeted therapy or chemotherapy for metastatic disease, based
on improved OS in this setting, as well as for neoadjuvant therapy
for HER2þ, locally advanced, inﬂammatory, or early breast cancer,
based on an improvement in pathologic complete response rate
[14e17]. Lapatinib-based therapies have been successfully
approved in estrogen receptorenegative and epositive cohorts due
to the effectiveness of lapatinib in combination with capecitabine
as a second-line therapy and in combination with letrozole [18,19].
Also, recent improvements in OS have been seen with second-linender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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these ﬁndings, lapatinib and T-DM1 are both approved as second-
line HER2-targeted therapies in patients with advanced or meta-
static HER2þ breast cancer who have progressed on prior therapy
with trastuzumab [19,21].
Although reports continue to emerge about the usefulness of
targeted therapy for recurrent HER2þ disease in the ﬁrst-line
setting, including the recent improvement in OS recently re-
ported with pertuzumab [22], nearly 70% of these patients will
experience acquired resistance and some will still exhibit primary
resistance [23]. Primary resistance might occur because of lack of
target dependency or activation of compensatory pathways [24].
Acquired resistance, which develops in most patients with
advanced disease, may result from loss of expression of the target
because of continuous therapy, activation of mutations down-
stream from the target, or activation of mechanisms that promote
cell proliferation [24]. Determination of molecular mechanisms
underlying resistance is necessary to improve outcomes for pa-
tients with HER2þ tumors [3], by allowing the selection of patients
who are likely to beneﬁt from speciﬁc therapies and the develop-
ment of strategies to overcome resistance [25].
Mechanisms of resistance to HER2-targeted therapy
Various factors associated with resistance to HER2-targeted
therapies have been proposed [25,26], which may be generally
classiﬁed as factors associated with receptor-level effects or those
of downstream signaling components.
Receptor-level factors affecting drug binding and action might
contribute to resistance. p95HER2, a HER2 fragment lacking the
extracellular binding domain, is unable to bind trastuzumab but
might retain sensitivity to other HER2-targeted therapies that bind
intracellularly [27,28]. Also, loss of HER2 ampliﬁcation has been
reported in patients with signiﬁcant residual disease after neo-
adjuvant trastuzumab therapy and is associated with poor
recurrence-free survival [29]. Increased activation of HER3 has also
been proposed as a contributor to resistance because increased
HER-family activating ligands have been detected in cells resistant
to trastuzumab, which does not inhibit HER2-HER3 hetero-
dimerization [30], and inhibiting HER2 has been shown to reac-
tivate HER3 [31e33].
Factors associatedwith downstream signaling components have
also been investigated as factors related to resistance to HER2-
targeted therapies. Alterations in regulation of downstream
signaling might lead to aberrant activation of signaling pathways
downstream of HER2 [34,35]. Also, compensatory crosstalk with
other pathways, such as between HER2 and HER3, epidermal
growth factor receptor (EGFR)/HER1, and insulin-like growth factor
1 receptor (IGF-1R), has been reported to reduce the effectiveness
of trastuzumab [36e38], and crosstalk between the estrogen re-
ceptor pathway and HER2 and the PI3K/Akt/mTOR pathway has
been implicated in endocrine resistance [39].
Current management options for resistance to HER2-targeted
therapy
Disease will eventually progress in patients with HER2þ meta-
static breast cancer who initially respond to HER2-targeted therapy
[40]. Various treatment strategies to overcome resistance to HER2-
targeted therapy have been assessed.
One strategy is to maintain trastuzumab therapy beyond pro-
gression because there have been several reports of the beneﬁts of
continued trastuzumab therapy with progressive disease [41e48],
which might be attributed to an additive action of trastuzumab in
combination with chemotherapy. However, additional prospectiveand larger clinical studies are necessary to elucidate the role of
continued use of HER2-targeted therapy and the appropriate
concomitant chemotherapeutic agents to use after disease
progression.
Because some tumors resistant to HER2-targeted therapy
depend on HER2-mediated signaling, another approach to man-
aging resistance is to switch HER2-targeted therapy. Data are
available for novel agents in the setting of trastuzumab resistance.
A phase 3, randomized, open-label study evaluating the dual
HER2-speciﬁc and EGFR/HER1-speciﬁc tyrosine kinase inhibitor
(TKI) lapatinib in combination with capecitabine versus capecita-
bine alone reported signiﬁcant improvements in time-to-
progression (TTP) (8.4 vs 4.4 months; hazard ratio [HR], 0.49;
95% conﬁdence interval [CI] ¼ 0.34e0.71; p < 0.001) and
progression-free survival (PFS) (8.4 vs 4.1months; HR, 0.47; 95% CI,
0.33e0.67; p < 0.001) at a planned interim analysis, prompting
early termination of the study and subsequent crossover of the
study treatment arms [18]. Based on this phase 3 data, lapatinib is
approved in combination with capecitabine for use in HER2þ
metastatic breast cancer that progresses with trastuzumab ther-
apy [18,19]. T-DM1 is an antibodyedrug conjugate with the anti-
tumor properties of trastuzumab and the cytotoxic activity of DM1,
a microtubule inhibitor (maytansine derivative). T-DM1 mono-
therapy is approved for the management of HER2þ metastatic
breast cancer in patients who previously received trastuzumab
and a taxane [21]. This approval was based on phase 3 data from a
randomized, open-label study that reported a prolonged PFS (9.6
vs 6.4 months; HR, 0.65; 95% CI, 0.55e0.77; p < 0.001) and OS (30.9
vs 25.1 months; HR, 0.68; 95% CI, 0.55e0.85; p < 0.001) for T-DM1
versus combination therapy with lapatinib and capecitabine [20].
The ﬁndings of this study was conﬁrmed by a recently published,
phase 3, randomized, open-label trial comparing T-DM1 and
physician's choice of therapy in patients with HER2þ advanced
breast cancer who had received two or more HER2-targeted
therapies [49]. T-DM1 was associated with a signiﬁcant improve-
ment in PFS compared with physician's choice of therapy (6.2 vs
3.3 months; HR, 0.528; 95% CI, 0.422e0.661; p < 0.0001); an
interim OS analysis showed a trend in favor of T-DM1 (HR, 0.552;
95% CI, 0.369e0.826; p ¼ 0.0034), but the efﬁcacy-stopping
boundary was not crossed [49].
Combining HER2 inhibitors has also been used as a strategy to
manage resistant disease because there is preclinical evidence of a
synergistic effect of the agents when used in combination [50e52].
In a phase 3, randomized, open-label study of patients with HER2þ
early breast cancer, the pathologic complete response rate asso-
ciated with lapatinib in combinationwith trastuzumab (51.3%) was
higher than that with either trastuzumab (29.5%) or lapatinib
(24.7%) given alone (p ¼ 0.0001 for combination vs trastuzumab;
p ¼ 0.34 vs lapatinib), resulting in an odds ratio of 2.6 (97.5% CI,
1.50e4.58; p ¼ 0.0001) for combination therapy versus trastuzu-
mab alone [53]. The ﬁndings of another phase 3, randomized,
open-label study in patients with metastatic breast cancer resis-
tant to trastuzumab demonstrated a signiﬁcant improvement in
PFS with trastuzumab in combination with lapatinib versus lapa-
tinib monotherapy (12.0 vs 8.1 weeks; HR, 0.73; 95% CI, 0.57e0.93;
p ¼ 0.008), although no signiﬁcant difference in OS (51.6 vs 39.0
weeks; HR, 0.75; 95% CI, 0.53e1.07; p ¼ 0.106) was seen between
the two treatment groups [54]. Combination therapy with tras-
tuzumab and pertuzumab was assessed in a phase 2 study of pa-
tients with advanced breast cancer that progressed during
trastuzumab therapy(55) Trastuzumab and pertuzumab reported
an objective response rate (ORR) of 24%, a clinical beneﬁt rate
(CBR) of 50%, a median PFS of 5.5 months (80% CI, 18e31), and a
median TTP of 3.9 months [55]. Another analysis of patients with
prior trastuzumab treatment who received pertuzumab
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mined that the combination of pertuzumab and trastuzumab
showed a greater beneﬁt than pertuzumab monotherapy (ORR
17.6% vs 3.4%; CBR 41.2% vs 10.3%; median PFS 17.4 vs 7.1 weeks;
median TTP 17.4 vs 7.1 weeks) [56].Fig. 1. Role of the PI3K/Akt/mTOR signaling pathway in HER2-mediated signal trans-
duction in breast cancer and target sites of action of PI3K/Akt/mTOR inhibitors [66].
4E-BP1, 4E-binding protein 1; Akt, protein kinase B; GF, growth factor; HER, human
epidermal growth factor receptor; mTOR, mammalian target of rapamycin; PI3K,
phosphatidylinositol 3-kinase; PHAS-1, phosphorylated heat-stable and acid-stable
protein; P, phosphorylation; PTEN, phosphatase and tensin homolog; RTK, receptor
tyrosine kinase; T-DM1, trastuzumab emtansine.
Adapted from Clinical Breast Cancer, 10(suppl 3) Evolving Strategies for Overcoming
Resistance to HER2-Directed Therapy: Targeting the PI3K/Akt/mTOR Pathway, s72-s78.
Copyright 2015) with permission from Elsevier.Investigational management options for resistance to HER2-
targeted therapy
A number of novel HER2-targeted treatment options are
currently undergoing clinical investigation in patients with HER2-
resistant breast cancer. Pertuzumab is being assessed in HER2-
resistant breast cancer, with an ongoing phase 2 trial of pertuzu-
mab in combination with trastuzumab and paclitaxel
(ClinicalTrials.gov identiﬁer NCT01276041) reporting a preliminary
6-month PFS rate of 81% (95% CI, 67e91) based on data from 36
evaluable patients (53 patients were enrolled) [57]. A recent phase
2 study of eribulin in combination with trastuzumab for locally
recurrent or metastatic HER2þ breast cancer demonstrated the
acceptability of this treatment option in this setting, reporting an
ORR of 71.2% (95% CI, 56.9e82.9), a disease control rate of 96.2%
(95% CI, 86.8e99.5), a CBR of 84.6% (95% CI, 71.9e93.1), and a me-
dian PFS of 11.6 months (95% CI, 9.1e13.9) [58]. Another phase 2
trial is currently assessing pertuzumab in combination with eri-
bulin and trastuzumab in recurrent HER2þ breast cancer
(ClinicalTrials.gov identiﬁer NCT01912963). A phase 3 trial
comparing combined treatment with trastuzumab and capecita-
bine with or without pertuzumab in patients with HER2þ meta-
static breast cancer that has progressed on prior trastuzumab
therapy is currently ongoing (ClinicalTrials.gov identiﬁer
NCT01026142).
Other novel, targeted therapies are also undergoing clinical
development in the setting of HER2-resistant breast cancer. Phase
1/2 trials evaluating the IGF-1R inhibitors BMS-754807 and cix-
utumumab are being conducted in patients with HER2-resistant
breast cancer (ClinicalTrials.gov identiﬁers NCT00788333 and
NCT00684983, respectively). The results of a recent phase 2 study
comparing the irreversible multi-TKI neratinib with lapatinib plus
capecitabine did not demonstrate improvements in PFS (4.5 vs 6.8
months; HR, 1.19; 95% CI, 0.89e1.60; p ¼ 0.231) or OS (19.7 vs 23.6
months; p ¼ 0.280) [59]. Monotherapy with another irreversible
TKI, afatinib, was also assessed in a phase 2 study of patients with
HER2þ metastatic breast cancer who progressed on trastuzumab,
providing a PFS of 15.1 weeks (95% CI, 8.1e16.7) and OS of 61.0
weeks (95% CI, 56.7enot evaluable) [60]. A series of ongoing phase
2 and 3 trials are being conducted to assess afatinib in combination
with chemotherapy in trastuzumab- or lapatinib-resistant breast
cancer (ClinicalTrials.gov identiﬁers NCT01125566, NCT01271725,
and NCT01441596) [61e63]. In trastuzumab-refractory, HER2þ
breast cancer, promising results of a phase 2 study were previously
reported for tanespimycin (CBR 59%; PFS 6 months; OS 17 months)
[64], although development of this agent has since been dis-
continued. Finally, combination therapy with the vascular endo-
thelial growth factor (VEGF) inhibitor pazopanib and lapatinib in a
phase 2 study of relapsed or refractory HER2þ inﬂammatory breast
cancer reported a numerical improvement in ORR between the
combination therapy and lapatinib monotherapy groups (58% vs
47%), but did not demonstrate an improvement in PFS (both 16.0
weeks) [65]. Therapies targeting downstream signaling pathways,
such as the PI3K/Akt/mTOR pathway, have also shown great
promise in overcoming resistance to HER2-targeted therapy in
breast cancer. The role of this pathway in HER2þ breast cancer and
the use of PI3K/Akt/mTOR inhibitors in HER2-resistant breast
cancer will be discussed next.Role of PI3K/Akt/mTOR pathway in HER2þ breast cancer
Resistance to HER2-targeted therapy might occur as a result of
aberrant activation of signaling pathways downstream of the re-
ceptor [25,34,35]. Because HER2 mediates signal transduction
through the PI3K/Akt/mTOR pathway [1], inhibition of components
of the PI3K/Akt/mTOR pathway might be a reasonable way to
overcome resistance and restore sensitivity to HER2-targeted
therapy (Fig. 1) [25,66,67]. Dysregulation of PI3K/Akt signaling
causes upregulation of the downstream mTOR pathway and
enhancement of messenger RNA translation and increased cellular
proliferation [68,69]], which are mediated by growth factor re-
ceptor overexpression and loss of the phosphatase and tensin ho-
molog (PTEN) tumor suppressor gene [70].
Breast cancer models of constitutively active PI3K/Akt/mTOR
pathway have shown resistance to HER2-targeted therapy [36], and
hyperactivity of the pathway associatedwith breast cancer includes
gain-of-function mutations in genes encoding PIK3CA, which en-
codes the catalytic subunit of PI3K, as well as mutations in AKT1,
ampliﬁcation of AKT2, and loss of PTEN [26]. PTENwas identiﬁed as
the only gene of the 8000 tested in which suppression led to
trastuzumab resistance [34], and patients with HER2þ tumors and
loss of PTEN function are more often resistant to trastuzumab
therapy and have shorter survival times [71]. The association of
PTEN loss and trastuzumab and lapatinib resistance has also been
reported [35,72].
PIK3CA gene mutations acquired during disease progression are
suggested to reﬂect increased activation of the PI3K pathway [25],
and in vitro data show that HER2 gene ampliﬁcation and PI3KCA
gene mutations are associated with resistance to HER2-targeted
agents [35,73e75]. Poorer clinical outcomes are reported after
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because of PTEN loss or PIK3CA gene mutations [34].
mTOR is a serine/threonine kinase that integrates multiple sig-
nals from growth factors and hormones, thereby controlling cell
growth, proliferation, and angiogenesis [6]. Positive regulators of
mTOR activity include IGF-1, IGF-1R, members of the ErbB family
and associated ligands, and VEGF receptors and associated ligands
[69]. Negative regulators of mTOR include PTEN, which inhibits
signaling through the PI3K/Akt pathway, and tuberous sclerosis
complex 1 (TSC1) and TSC2. Phosphorylation of TSC2 by Akt
upregulates mTOR activity. Dysregulated mTOR activation is
implicated in oncogenesis, angiogenesis, and drug resistance [6],
and HER2 overexpression is associated with activation of the mTOR
pathway and subsequent poor prognosis [76,77]. As multiple up-
stream components of the mTOR pathway become dysregulated in
breast cancer and are thought to be involved in oncogenesis, mTOR
inhibition has the potential to interfere with tumor progression at
several levels, and targeting multiple pathways with different
agents might be more effective than monotherapy strategies [6,78].
Because of the cytostatic nature of mTOR inhibitors, their combined
use with cytotoxic agents is suggested [36].PI3K/Akt/mTOR inhibitors in HER2-resistant breast cancer
Preclinical data support the use of inhibitors of the PI3K/Akt/
mTOR pathway after resistance to HER2-targeted therapy. Trastu-
zumab in combination with everolimus, an mTOR inhibitor,
restored sensitivity and inhibited growth of trastuzumab-resistant
cells [79]. With in vitro and in vivo models of trastuzumab resis-
tance, combination therapy with an mTOR inhibitor and trastuzu-
mab was more effective in inhibiting tumor growth than single-
agent therapy [80]. Other mTOR, PI3K, and dual PI3K/mTOR
inhibitors, including GDC-0941, NVP-BEZ235, NVP-BKM120, andTable 1
Efﬁcacy data from phase 1e3 trials evaluating everolimus in patients with HER2þ advan
Trial (phase) Number of evaluable patients Study treatment
NCT00426556
(phase 1b) [87]
33 patients enrolled, 27 had
measurable disease and
were evaluable for efﬁcacy
Everolimus þ trastuzumab þ pacl
NCT00426556
(phase 2) [88]





were evaluable for efﬁcacy
Everolimus (5, 20, or 30 mg/week
þ vinorelbine (25 mg/m2 on days
1 and 8 of 21-day cycle)
þ trastuzumab (2 mg/kg weekly)
BOLERO-3
(phase 3) [90,93]
569 Everolimus þ vinorelbine þ trastu
vs placebo þ vinorelbine þ trastu
CBR, clinical beneﬁt rate; CR, complete response; DCR, disease control rate; ORR, objec
disease.
aData are for the overall population.
bData are for the everolimus 5-mg/day cohort.
cData are for all grades.INK-128, have restored sensitivity to HER2-targeted therapy in
in vitro and in vivo models [35,81e86].
Several clinical studies are investigating the potential of mTOR
inhibitors to improve or overcome resistance to HER2-targeted
therapy; everolimus is the furthest in clinical development
(Table 1) [87e90]. The phase 1b dose-escalation study of ever-
olimus in combination with trastuzumab and paclitaxel in 33 pa-
tients with metastatic HER2þ breast cancer who experienced
progression on or after trastuzumab therapy reported an ORR of
44%, a disease control rate of 74%, and a median PFS of 34 weeks
(95% CI, 29.1e40.7) (ClinicalTrial.gov number NCT00426556) [87].
The phase 2 portion of the trial in patients with resistance to
trastuzumab and a taxane and who received everolimus (10 mg/
day) in combination with paclitaxel (80 mg/m2 on days 1, 8, and 15
every 4 weeks) and trastuzumab (4mg/kg loading dose followed by
2 mg/kg weekly) reported clinical beneﬁt and objective response
rates of 36% and 22%, respectively, and a median PFS of 5.5 months
(95% CI, 4.99e7.69) in the 55 evaluable patients [88]. The incidences
of adverse events (AEs) were consistent with the safety proﬁles of
the individual therapies. Grade 3/4 hematologic events included
neutropenia (grade 3, 26%; grade 4, 4%), anemia (grade 3, 7%; grade
4, 0), leukopenia (grade 3, 16%; grade 4, 2%), lymphopenia (grade 3,
18%; grade 4, 2%) and thrombocytopenia (grade 3, 6%; grade 4, 2%).
Grade 3/4 nonhematologic events included stomatitis (20%), diar-
rhea (6%), vomiting (6%), fatigue (6%), and pneumonia (6%); there
were no grade 4 nonhematologic events reported.
A phase 1/1b study assessed dose-limiting toxicities (DLTs) and
tumor response of everolimus in combination with trastuzumab
and vinorelbine in 50 patients with HER2þ advanced breast cancer
whose disease progressed or relapsed after previous trastuzumab
and chemotherapy (ClinicalTrials.gov number NCT00426530) [89].
Patients received everolimus 5 mg/day, 20 mg/week, or 30 mg/
week plus vinorelbine (25 mg/m2 on days 1 and 8 of a 21-day cycle)
and trastuzumab (2 mg/kg weekly; after a 4-mg/kg loading dose ifced breast cancer.
Efﬁcacy results Safety results (adverse events)c
itaxel ORR, 44%a
DCR, 74%a
Median PFS, 34 weeksa
 Most common hematologic events:
neutropenia (21%), lymphopenia (14%),
and leukopenia (14%)
 Most common nonhematologic events:




Median PFS, 5.5 months
 Most common hematologic events:
neutropenia (36%), anemia (35%), and
leukopenia (22%)
 Most common nonhematologic events:






 Most common hematologic event:
neutropenia (92%)




PFS, 7.00 vs 5.78 months
ORR, 41% vs 37%
(p ¼ 0.2108)
CR, 3% vs 2%
PR, 38% vs 35%
SD, 48% vs 41%
 Most common hematologic events in the
everolimus arm: neutropenia (82%), anemia
(49%), leukopenia (46%), febrile neutropenia
(17%), and thrombocytopenia (15%)
 Most common nonhematologic events in
the everolimus arm: stomatitis (62%),
fatigue (43%), pyrexia (39%), diarrhea (38%),
nausea (36%), and decreased appetite (32%)
tive response rate; PFS, progression-free survival; PR, partial response; SD, stable
S.T. Wilks / The Breast 24 (2015) 548e555552not receiving trastuzumab at study entry). Everolimus in combi-
nation with weekly vinorelbine and trastuzumab was well toler-
ated and manageable; neutropenia was the most common
hematologic AE (92%) and stomatitis the most common non-
hematologic AE (70%). Based on DLT ﬁndings, everolimus 5 mg/day
was chosen as the optimal daily dose in combination with weekly
trastuzumab and vinorelbine for further clinical development. In
the 5-mg/day everolimus cohort, the ORR was 19% and the CBR
was 50%. The median PFS in the 5-mg/day cohort was 30.7 weeks.
In the extension phase of the study, in which patients were
allowed to continue everolimus and vinorelbine could be dis-
continued at the investigator's discretion, two additional patients
achieved complete response, one achieved a partial response, and
the overall PFS was 41 weeks [91]. In patients receiving ever-
olimus 5 mg/day in combination with weekly trastuzumab and
vinorelbine, neutropenia (grade 1/2, 10%; grade 3/4, 83%) was the
most common hematologic AE and stomatitis (grade 1/2, 70%;
grade 3/4, 17%) the most common nonhematologic AE related to
study treatment.
A post hoc analysis of these two phase 1/2 trials evaluated the
efﬁcacy of everolimus in patients pretreated with lapatinib [92].
Among 101 evaluable patients, the ORR was 21% for those who
received previous lapatinib therapy and 29% in those who did not;
the disease control rate was 88% and 81%, respectively; and mean
PFS was 29.0 and 36.1 weeks, respectively [92], suggesting that
everolimus in combination with trastuzumab and chemotherapy
has promising efﬁcacy in HER2þ metastatic breast cancer, regard-
less of prior lapatinib therapy.
BOLERO-3 (ClinicalTrials.gov number NCT01007942) is a phase
3, randomized, double-blind, placebo-controlled, multicenter, in-
ternational clinical trial assessing the efﬁcacy of everolimus in
combination with trastuzumab and vinorelbine in 569 patients
with HER2þ advanced breast cancer resistant to trastuzumab who
have been previously treated with a taxane [90,93]. The primary
endpoint was PFS, and secondary endpoints include OS, ORR, and
safety. Study treatment was continued until progressive disease or
intolerable toxicity.
At the time of the ﬁrst reported analysis of the BOLERO-3 study
(data cutoff: March 15, 2013), themedian duration of follow-upwas
20 months, and 61 patients were continuing study treatment,
including 12% in the study arm and 10% in the control arm [90]. The
most common reason for discontinuation was disease progression,
with fewer patients discontinuing treatment because of disease
progression in the everolimus arm (68%) than in the control arm
(78%), while 10% of patients in the everolimus arm discontinued
treatment because of AEs, compared with 5% in the control arm.
The study population was heavily pre-treated, with all patients
having prior exposure to both trastuzumab and taxane therapies,
approximately 27% of patients having prior lapatinib exposure, and
42% of patients receiving at least two prior lines of chemotherapy
for metastatic disease. The median duration of exposure was highly
comparable across treatment groups for the individual drugs used
in the respective combinations.
The primary efﬁcacy analysis based on local radiologic assess-
ment resulted in an estimated 22% risk reduction for PFS (HR, 0.78;
95% CI, 0.65e0.95; p ¼ 0.0067) with everolimus therapy, corre-
sponding to a 1.22-month prolongation in median PFS, from 5.78
months in the control arm to 7.00 months in the everolimus arm
[90]. The PFS beneﬁt of everolimus was observed across patient
subgroups, deﬁned by demographic characteristics, prior therapy,
and disease characteristics. Patients with negative hormone re-
ceptor status had better PFS outcomes with everolimus therapy.
The ORR was similar between treatment arms. OS data are not yet
mature.The nonhematologic AE proﬁle of combination therapy with
everolimus was consistent with the known safety proﬁle of the
individual drugs, and no new unexpected AEs were observed
[90,93]. AEs typical of mTOR inhibitors occurred more frequently
with everolimus therapy and included stomatitis, noninfectious
pneumonitis, rash, and hyperglycemia, whereas the incidence and
grade of other nonhematologic AEs were similar between arms,
with the exception of grade 3/4 stomatitis (everolimus, 13%; pla-
cebo, 1%) and fatigue (everolimus, 12%; placebo, 4%). The most
common hematologic AEs in the everolimus treatment groups
were neutropenia (82%), anemia (49%), leukopenia (46%), febrile
neutropenia (17%), and thrombocytopenia (15%).
Other mTOR inhibitors under development in HER2-resistant
breast cancer include temsirolimus and INK128 (MLN0128), both
undergoing phase 1/2 clinical investigation (ClinicalTrials.gov
numbers NCT01111825 and NCT01351350, respectively). Investiga-
tional PI3K inhibitors under development include buparlisib
(BKM120), BYL719, pictilisib (GDC-0941), and XL147, and investi-
gational AKT inhibitors include MK2206, all currently under phase
1/2 clinical investigation in patients with HER2þ breast cancer who
either experienced disease progression with or received previous
trastuzumab therapy. In a phase 1/2 study of buparlisib in combi-
nation with trastuzumab in patients resistant to trastuzumab-
containing therapy, the maximum tolerated dose (MTD) of
BKM120 was 100 mg/day, and, in the 17 enrolled patients, two
achieved a partial response, and there were seven occurrences of
disease stabilization of at least 6 weeks in duration (ClinicalTrials.
gov number NCT01132664) [94]. Common AEs with the combina-
tion therapy included rash (39%), hyperglycemia (33%), and diar-
rhea (28%).
Conclusions
Therapies targeting HER2 have resulted in improved outcomes
for patients with HER2þ breast cancer. However, intrinsic and ac-
quired resistance to these therapies is an ongoing clinical challenge.
Elucidation of the molecular mechanisms underlying resistance is
leading to the identiﬁcation of therapies and strategies to manage
resistance to HER2-targeted therapies.
As HER2-overexpressing tumors use the PI3K/Akt/mTOR
pathway to develop resistance to HER2-targeted therapies, therapy
with inhibitors of this pathway is a rational approach. The combi-
nation of everolimus, an mTOR inhibitor, with HER2-targeted
therapies is a promising therapeutic strategy to overcome resis-
tance in patients with HER2þ advanced breast cancer, a strategy
that is supported by phase 3 data from the BOLERO-3 study. Other
promising inhibitors of the PI3K/Akt/mTOR are undergoing clinical
development.
As described by the authors of the BOLERO-3 study, everolimus
is thought to be the ﬁrst non-HER2etargeted therapy to speciﬁcally
address the postulated underlying molecular mechanism of tras-
tuzumab resistance [90]. The positive ﬁndings from BOLERO-3
suggest that aberrant intracellular signaling pathways contribute
to the genesis of trastuzumab resistance, and justify investigation of
additional treatment strategies, including mTOR inhibitors in
combination with other HER2-targeted therapies.
Ongoing clinical investigation should provide further insight
into the appropriate management of HER2-resistant breast cancer.
As well, to achieve maximum clinical efﬁcacy through individual-
ized administration of targeted agents, there is a need to identify
predictive biomarkers. This could result in optimization of treat-
ment strategies for individual patients, allowing both patient
stratiﬁcation based on previous treatment exposure or sensitivity
and identiﬁcation of tumor phenotypes in responding patients.
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